Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost–effectiveness and budget impact

Rognoni, Carla; Gerzeli, Simone

doi:10.2217/cer-2019-0074

Cited by 16 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study concluded that PBM was a cost-effective option and has cost-saving potential in hip and knee arthroplasties and CABG in Turkey. This finding is in line with examples from other health-care systems, 15 , 43 , 44 and is similar to results reported in earlier literature; it concludes that implementing just the first pillar of PBM can be a cost-effective option and may provide considerable cost-saving opportunities to the SSI. In the cost-effectiveness analysis, the incremental cost per avoided postoperative adverse event was used as the decision criterion.…”

Section: Discussionsupporting

confidence: 91%

Cost-Effectiveness and Budget Impact of Comprehensive Anemia Management, The First Pillar of Patient Blood Management, on the Turkish Healthcare System

Tatar¹,

Alkış²,

Güçlü³

et al. 2022

CEOR

View full text Add to dashboard Cite

Purpose Patient blood management (PBM) is a patient-centered, evidence-based, multidisciplinary approach aimed at optimizing hemoglobin concentration, ensuring the continuity of hemostasis and minimizing blood loss in patients undergoing surgery. The aims of this study were: (1) to explore the cost-effectiveness of comprehensive anemia management, the first pillar of PBM, in non-cardiac and cardiac surgery from the Turkish Social Security Institution’s (SSI’s) perspective; and (2) to explore the potential budget impact of PBM for coronary artery bypass grafting (CABG) and hip and knee arthroplasty to the SSI. Methods Cost-effectiveness and budget impact models were developed based on the avoided postoperative adverse events following implementation of the first pillar of PBM for non-cardiac and cardiac surgical patients. The probabilities of adverse events (sepsis with and without pneumonia, renal failure, myocardial infarction and stroke) were taken from a recent meta-analysis and the costs of treating these adverse events to the SSI were estimated through expert views and the use of SSI guidelines. Results The PBM arm dominated the control arm for both non-cardiac and cardiac surgeries in terms of cost-effectiveness in the simulated cohort of patients and was associated with improved outcomes and lower costs (1768 and 1244 avoided adverse events, and incremental cost reductions for non-cardiac and cardiac surgery of 7504 Turkish lira [TRY] and 6102 TRY, respectively). The budget impact analysis showed that PBM is a potential cost-saving option for the SSI, with savings of up to 196,937,705 TRY (€12,841,697) for hip and knee arthroplasty and 24,642,504 TRY (€1,606,861) for CABG surgery. Conclusion PBM is a cost-effective option with a potential of cost-saving for cardiac and non-cardiac surgery in Turkey.

show abstract

Section: Discussionsupporting

confidence: 91%

Cost-Effectiveness and Budget Impact of Comprehensive Anemia Management, The First Pillar of Patient Blood Management, on the Turkish Healthcare System

Tatar¹,

Alkış²,

Güçlü³

et al. 2022

CEOR

View full text Add to dashboard Cite

show abstract

“…This economic analysis was based on data for patients with a recent AHF episode, representing a very high‐risk subgroup of patients with HF; however, the findings are applicable to all patients with HF and align with those from prior economic analyses in patients with chronic HF and ID: in the FAIR‐HF trial, FCM was cost‐effective vs. placebo from UK, 27 Spanish 5 and Swedish 28 health service perspectives. Similarly, a pooled analysis of patient‐level data from FAIR‐HF, FER‐CARS‐01, CONFIRM‐HF and EFFICACY‐HF trials found that FCM was dominant vs. placebo in an Italian healthcare setting 19 and cost‐saving over 5 years in a French healthcare setting. 29 These data support our findings and suggest that FCM is cost‐effective in a broad spectrum of patients with HF and ID.…”

Section: Discussionmentioning

confidence: 97%

“…The difference in a small incremental cost for gain in QALYs, as for Italy, is in part due to the higher estimated background HF maintenance cost for Italy. The cost was derived from the work of Rognoni and Gerzeli 19 who, in performing an economic analysis of FCM in the Italian setting, reported costs for a model based on New York Heart Association (NYHA) classes. If these costs were lower, then, like the other countries, the intervention tends towards dominance.…”

Section: Discussionmentioning

confidence: 99%

Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF

McEwan

Ponikowski

Davis

et al. 2021

European J of Heart Fail

View full text Add to dashboard Cite

Iron deficiency is common in patients with heart failure (HF). In AFFIRM-AHF, ferric carboxymaltose (FCM) reduced the risk of hospitalisations for HF (HHF) and improved quality of life vs. placebo in iron-deficient patients with a recent episode of acute HF. The objective of this study was to estimate the cost-effectiveness of FCM compared with placebo in iron-deficient patients with left ventricular ejection fraction <50%, stabilised after an episode of acute HF, using data from the AFFIRM-AHF trial from Italian, UK, US and Swiss payer perspectives.

show abstract

“…The BI analyses of FCM in patients with CHF have also showed cost savings or a minimal BI in other European countries. A recent combined CEA and BI study within the Italian Healthcare System using the same model resulted in savings of e382 per patient per year 33 . In France, with a time horizon of 5 years, the savings were of e5 per patient (e2.5 in the first year) 34 , while in Romania, those were e9 per patient over 1 year 35 .…”

Section: Discussionmentioning

confidence: 99%

Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain

Delgado

Oliva

González-Franco

et al. 2020

Journal of Medical Economics

View full text Add to dashboard Cite

Objective: The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study aims to evaluate the budget impact for the Spanish National Health System (SNHS) of treating ID in reduced LVEF CHF with FCM compared to non-iron treatment. Methods: We simulated a hypothetical cohort of 1000 CHF patients with ID and reduced LVEF based on the Spanish population characteristics. A decision-analytic model was also built using the data from the largest FCM clinical trial (CONFIRM-HF) that lasted for a year. We considered the use of healthcare resources from a national prospective study. A deterministic sensitivity analysis was carried out varying the corresponding baseline data by ±25%. Results: The cost of treating the simulated population with FCM was e2,570,914, while that of the non-iron treatment was e3,105,711, which corresponds to a cost saving of e534,797 per 1,000 patients in one year. Cost savings were mainly due to a decrease in the number of hospitalizations. All sensitivity analysis showed cost savings for the SNHS. Conclusions: FCM results in an annual cost saving of e534.80 per patient, and would thus be expected to reduce the economic burden of CHF in Spain.

show abstract

Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost–effectiveness and budget impact

Cited by 16 publications

References 31 publications

Cost-Effectiveness and Budget Impact of Comprehensive Anemia Management, The First Pillar of Patient Blood Management, on the Turkish Healthcare System

Cost-Effectiveness and Budget Impact of Comprehensive Anemia Management, The First Pillar of Patient Blood Management, on the Turkish Healthcare System

Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF

Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain

Contact Info

Product

Resources

About